With just two weeks left in Q2 2026 reporting and about four weeks before Q3 earnings begin, S&P 500 earnings per share (EPS) estimates have grown remarkably, rising 50% in 18 months to an expected $363.71 by year-end 2026. This surge is largely due to a significant markup from Anthropic, which contributed 15% to Q2 EPS growth, excluding other factors like tariff refunds. However, this rapid growth is considered unlikely to be sustainable. The current EPS estimates mark the first time quarterly EPS has reached $100 levels, highlighting an unusual spike influenced by specific company impacts rather than broad market trends.
The S&P 500 quarterly EPS estimate has reached an unprecedented $100 per share, reflecting a 50% rise over 18 months to an expected $363.71 by year-end 2026. For readers following US stocks on Pluang, here is the market snapshot as of Sep 19, 2026 08:11 WIB: out of 150 priced US stocks, 52 rose and 97 fell today. Notable movers include Micron Technology (MU) at USD 1,015.80 with a 1-day change of +3.92% and a typical hold time of 46 days, Zoom Video Communications (ZM) at USD 88.77 down 3.68% with 100% buy order activity, and Spotify Technology (SPOT) at USD 509.45 down 3.67% with 88% sell order activity.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
